In a small portion of insulinoma patients (<5–10%), the overexpresses of glucagon-like peptide-1 (GLP-1) can be a target for scintigraphy with radiolabeled GLP-1 receptor analogues [31]. This evidence concerns the gene GCG and pancreatic insulinoma.